Trial Profile
A Phase II Study of Lenalidomide for Adult Histiocyte Disorders
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Erdheim-Chester disease; Langerhans cell histiocytosis; Sarcoma
- Focus Therapeutic Use
- 14 Feb 2024 Planned End Date changed from 1 Sep 2024 to 1 Aug 2024.
- 15 Jun 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 15 Jun 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Feb 2024.